Is “Delitigation” Associated with a Change in Product Safety? The Case of Vaccines
This study investigates whether the threat of litigation induces firms to provide safer products in a regulated industry. I analyze whether removing litigation risk or “delitigation” of product liability is associated with a change in the safety of vaccines. Using U.S. nationwide and state-level data, I find that vaccines that were licensed after legislation that preempted most product liability lawsuits are associated with a significantly higher incidence of adverse events than were vaccines that were licensed under a previous regime that permitted consumers to sue. Oaxaca decomposition suggests that the difference is due to the policy change. The results suggest that product safety deteriorates when consumers are no longer able to sue manufacturers.
KeywordsLitigation risk Oaxaca decomposition Product liability Product safety Vaccine safety
I am grateful for valuable comments from Lawrence White (the Editor) and two anonymous referees. I also thank Mary Holland, Robert Krakow, Susan Lee, Anthony Mawson, Jonathan Rose, David Yermack, and participants of the International Atlantic Economics Society 2013 conference, Pennsylvania Economics Association 2015 conference, and Baruch College seminar series for insightful comments. Any errors or omissions are my own.
Wasserman Endowment at Baruch College.
Compliance with Ethical Standards
Conflict of interest
The author filed a claim under the U.S. National Vaccine Injury Compensation Program, a program established under the National Childhood Vaccine Injury Act, for her daughter. The Office of Special Masters in the U.S. Court of Federal Claims dismissed the claim on the basis of untimely filing.
- Biddle, T. M., Green, E. M., Mannix, R. J. & Winkelman, S. L. (2002). Industry standards as a source of liability for trade associations and association members. Retrieved August 10, 2014 from http://www.crowell.com/documents/DOCASSOCFKTYPE_ARTICLES_506.pdf.
- Boulianne, N., De Serres, G., Duval, B., Joly, J. R., Meyer, F., Dery, P., et al. (1991). Major measles epidemic in the region of Quebec despite a 99% vaccine coverage. Canadian Journal of Public Health, 82(3), 189–190.Google Scholar
- Bruesewitz v. Wyeth. (2011). 562 U.S. 223. Retrieved March 27, 2017 from https://supreme.justia.com/cases/federal/us/562/09-152/.
- Centers for Disease Control and Prevention. (1997). Poliomyelitis prevention in the United States. MMWR Recommendations and Reports, 46 (RR-3) (pp. 1–25).Google Scholar
- Centers for Disease Control and Prevention. (1999a). Rotavirus vaccine (rotashield) and intussusception. Retrieved January 3, 2013 from http://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-rotashield-historical.htm.
- Centers for Disease Control and Prevention. (1999b). Withdrawal of rotavirus vaccine recommendation. MMWR. Morbidity and Mortality Weekly Report, 48(43), 1007.Google Scholar
- Classen, J. B. (2014). Review of vaccine induced immune overload and the resulting epidemics of type 1 diabetes and metabolic syndrome. Journal of Molecular and Genetic Medicine, S1, 25–29.Google Scholar
- Coulter, H. L., & Fisher, B. L. (1991). A shot in the dark. New York: Penguin Group.Google Scholar
- Dell’Antonia, K. J. (2013). Will parents still turn down an ‘anti-cancer vaccine’? Retrieved March 3, 2017 from https://mobile.nytimes.com/blogs/parenting/2013/06/19/will-parents-still-turn-down-an-anti-cancer-vaccine/.
- Dodd, D. (2003). Benefits of combination vaccines: Effective vaccination on a simplified schedule. American Journal of Managed Care, 9, S6–S12.Google Scholar
- Gottsdanker v. Cutter Laboratories. (1960). 182 cal.App.2d 602, 6 cal.Rptr. 320, 79 a.L.R.2d 290 (cal.App. 1 dist. Jul 12). Retrieved March 1, 2017 from http://law.justia.com/cases/california/court-of-appeal/2d/182/602.html.
- Harper, D. M., & Williams, K. B. (2010). Prophylactic HPV vaccines: Current knowledge of impact on gynecologic premalignancies. Discovery Medicine, 10(50), 7–17.Google Scholar
- Institute of Medicine. (1993). The children’s vaccine initiative: Achieving the vision. Washington, DC: National Academy Press. Retrieved January 15, 2014 from http://www.nap.edu/catalog/2224.html.
- Institute of Medicine. (2000). Vaccines for the 21st century: A tool for decisionmaking. Retrieved January 15, 2014 from http://www.nap.edu/catalog/5501.html.
- Institute of Medicine. (2013). The childhood immunization schedule and safety. Washington, DC: The National Academies Press.Google Scholar
- Kessler, D., & Vladeck, D. (2008). A critical examination of the FDA’s efforts to preempt failure-to-warn claims. Georgetown Law Journal, 96, 461–495.Google Scholar
- King, A. J., Van Der Lee, S., Mohangoo, A., Van Gent, M., Van Der Ark, A., & Van De Waterbeemd, B. (2013). Genome-wide gene expression analysis of bordetella pertussis isolates associated with a resurgence in pertussis: Elucidation of factors involved in the increased fitness of epidemic strains. PLoS ONE, 8(6), e66150.CrossRefGoogle Scholar
- Lasker, C. A. (2011). Private securities litigation reform act: Safe harbor for the innocent or modern day Port of Tortuga for the buccaneers of Wall Street? Journal of Corporation Law, 36(3), 654–675.Google Scholar
- Legal Information Institute. (2013). Rule 37. Failure to make disclosures or to cooperate in discovery; sanctions. Retrieved August 3, 2014 from http://www.law.cornell.edu/rules/frcp/rule_37.
- Marin, M., Broder, K. R., Temte, J. L., Snider, D. E., & Seward, J. F. (2010). Use of combination measles, mumps, rubella, and varicella vaccine. MMWR Recommendations and Reports, 59(RR-3), 1–12.Google Scholar
- National Vaccine Information Center (NVIC). (2013). Dose-adjusted graphs and tables. Retrieved September 2, 2013 from http://www.medalerts.org/vaersdb/doses/index.php.
- Otake, T. (2016). Cervical cancer vaccine suit filed over side effects. Retrieved March 3, 2017 from http://www.japantimes.co.jp/news/2016/07/27/national/crime-legal/cervical-cancer-vaccine-suit-filed-over-side-effects/#.WLlxW28rJph.
- Philipson, T. J., Sun, E., & Goldman, D. (2011). The effects of product liability exemption in the presence of the FDA. In D. P. Kessler (Ed.), Regulation vs litigation: Perspectives from economics and law (pp. 137–163). Chicago: University of Chicago Press.Google Scholar
- Polinsky, M., & Shavell, S. (2010). The uneasy case for product liability. Harvard Law Review, 123(6), 1438–1492.Google Scholar
- Salk, J. (1984). Statement on national childhood vaccine injury compensation act. Retrieved May 11, 2014 from http://files.eric.ed.gov/fulltext/ED255480.pdf.
- Sotomayor, S. (2011). Dissent of Bruesewitz v. Wyeth LLC. Retrieved March 27, 2017 from https://supreme.justia.com/cases/federal/us/562/09-152/dissent.html.
- Toner v. Lederle Laboratories. (1987). 828 f.2d 510. Retrieved March 27, 2017 from https://law.resource.org/pub/us/case/reporter/F2/828/828.F2d.510.84-3906.html.
- Trebilcock, M., & Veel, P.-E. (2013). Chapter 22: No-fault accident compensation systems. In J. Arlen (Ed.), Research handbook on the economics of torts (pp. 588–607). Northampton, MA: Edward Elgar.Google Scholar
- U.S. Congress House of Representatives: Committee on Energy and Commerce. (1984). Hearings before the subcommittee on health and environment on H.R. 5810, 98th Congress, 2nd session. Retrieved March 1, 2014 from http://babel.hathitrust.org/cgi/pt?id=mdp.39015042797467;view=1up;seq=1.